STAT

From chemicals to life: Scientists try to build cells from scratch

A growing number of collaborations are melding their efforts together in pursuit of an audacious goal: building a living cell out of non-living molecules.

Various scientists around the world are trying to build cells from scratch. Marileen Dogterom has been piecing together a cytoskeleton in the Netherlands. Kate Adamala is attaching receptors to a lipid bilayer in Minnesota. And Tetsuya Yomo built RNA that can evolve like the real thing in Japan.

But by and large they’ve been working independently on different cell parts. Now, a growing number of collaborations are melding these efforts together and speeding progress toward an audacious goal: building a living cell out of non-living molecules.

It’s an idea that’s been bandied about for decades, but scientists say recent technological advances have rendered viable what was once a pipe dream. A cell constructed from the ground up would let researchers better test drugs, enable bioengineers to build the next generation of cellular machines, and help biologists answer the fundamental question: What does it mean to be alive?

And funders and university administrators are increasingly backing such a goal. A 25 million euro Dutch project across six universities to work on building a synthetic

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About GLP-1 Spending, Biosimilar Patient Costs, And More
Spending on GLP-1 drugs like Ozempic and Wegovy ballooned last year and they're set to cost the U.S. health care system and the federal government still more.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FTC Fighting ‘Junk’ Patents, Pfizer Direct-to-consumer Plans, And More
The FTC expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings for 20 different brand-name treatments.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

Related Books & Audiobooks